Abstract
We appreciate both Dr. Gehrs' (1) careful examination of our study (2) on the efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy and the opportunity to respond to her thoughtful comments. In response to her question concerning the baseline scores, the control group and octreotide-treated group baseline Early Treatment of Diabetic Retinopathy Study (ETDRS) scores were not different, with mean (± SD) values of 51.6 ± 4.0 for control and 51.6 ± 4.8 for treated groups. Although a reading center was not used in this pilot study, each retinal specialist used identical criteria for …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
